Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 108
- Registration Number
- NCT00002558
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 800
- Registration Number
- NCT00002894
- Locations
- 🇬🇧
Middlesex Hospital- Meyerstein Institute, London, England, United Kingdom
Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Children's Hospital Los Angeles
- Registration Number
- NCT00025324
- Locations
- 🇺🇸
Children's Hospital of the King's Daughters, Norfolk, Virginia, United States
🇨🇦Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 46
- Registration Number
- NCT00025285
- Locations
- 🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Chemotherapy in Treating Children With Liver Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Societe Internationale d'Oncologie Pediatrique
- Target Recruit Count
- 260
- Registration Number
- NCT00003912
- Locations
- 🇮🇹
Azienda Ospedaliera di Padova, Padova, Italy
Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 600
- Registration Number
- NCT00003159
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
🇬🇧Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Societe Internationale d'Oncologie Pediatrique
- Registration Number
- NCT00025441
- Locations
- 🇬🇧
Saint Bartholomew's Hospital, London, England, United Kingdom
🇬🇧Bristol Royal Hospital for Children, Bristol, England, United Kingdom
🇬🇧Oxford Radcliffe Hospital, Oxford, England, United Kingdom
Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Societe Internationale d'Oncologie Pediatrique
- Target Recruit Count
- 100
- Registration Number
- NCT00025428
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
🇨🇭Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇦🇹St. Anna Children's Hospital, Vienna, Austria
Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Societe Internationale d'Oncologie Pediatrique
- Target Recruit Count
- 400
- Registration Number
- NCT00002898
- Locations
- 🇬🇧
Institute of Child Health, Bristol, England, United Kingdom
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 98
- Registration Number
- NCT00039195
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.